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ABSTRACT 
The tumor suppressor p53 was identified 35 years ago and has since then been studied extensively, but despite 
all efforts, no drug or therapy directly involving it has been clinically approved - yet! A lot of potential new 
drugs are on their way that can reactivate p53 function by various mechanisms. Even a whole new approach 
called cyclotherapy has been established, during which p53 is activated in normal cells to protect patients from 
the adverse effects of chemotherapy while tumor cells are still being killed efficiently. In this thesis, 16 drug 
combinations are being described in this context (paper I). Four individual p53-activating compounds, i.e. 
tenovin-6, leptomycin B (LMB), nutlin-3 and actinomycin D at low doses (LDactD), were used prior to the 
addition of each one clinically approved chemotherapeutic agent, i.e vinblastine, vinorelbine, cytosine 
arabinoside or gemcitabine. LDactD, which is clinically approved, showed the most promising results.  
Unexpectedly, we identified two compounds that can inhibit p53’s ability to induce p21, i.e. the novel SirT2 
inhibitor tenovin-D3 (paper II) and the widely used histone deacetylase inhibitor (HDACi) trichostatin A (TSA) 
(paper III). Inhibition of p21 in tumor cells might be desirable during cancer treatment to prevent tumor cells 
from undergoing cell cycle arrest, which would make them more vulnerable to classic chemotherapy. On the 
other hand, an inhibition of cell cycle arrest in normal cells might occur, which may worsen the side effects 
caused by chemotherapy. However, SirT2 plays a role in neurodegenerative diseases, and hence compounds like 
tenovin-D3 may be of use in the treatment thereof. Furthermore, the decrease in p21 levels may be a contributing 
factor in the previously observed increase in efficacy during the generation of induced pluripotent stem cells 
upon treatment with TSA; also tenovin-D3 could be useful in this context.  
With the aid of a cell-based screen we identified two small molecules that can activate p53:  
1) MJ05 was one of the most active hit compounds and was very selective (paper IV); it was highly cytotoxic 
in ARN8, especially when combined with nutlin-3, whereas it was cytostatic or had a very mild effect in 
other tumor cell lines and normal cells. It inhibited tumor growth in vivo, an effect that was enhanced upon 
co-treatment with nutlin-3. Furthermore, MJ05 selectively killed chronic myelogenous leukemia stem cells 
ex vivo while having milder effects in leukocyte stem cells derived from cord blood. Preliminary data 
strongly suggest that MJ05 acts by inhibition of pyrimidine (deoxy-) nucleotide synthesis.  
2) Despite being a hit compound in our screen, MJ25 was not very potent at activating p53 (paper V). 
Nevertheless, its ability to inhibit thiredoxin reductase 1 (TrxR1) and its selectivity towards melanoma cell 
lines compared with normal cells were interesting features. We compared it with the TrxR1 inihibitor 
auranofin, which was very potent and selective at killing melanoma cells in cell viability assays. The 
insolubility of MJ25 at concentrations required for in vivo studies prevented us from testing it on xenografts 
in mice. Furthermore, MJ25 might not be specific for TrxR1, so the identification of additional targets could 
be investigated in the future. Auranofin, the other hand, has a more defined mechanism of action and is 
clinically approved for the treatment of rheumatoid arthritis. These traits combined with its potentially 
selective cytotoxic effect at low micromolar concentrations in melanoma cells may turn this compound into 
a potential drug candidate to be tested in patients suffering from malignant melanoma. 
In the final study presented in this thesis (paper VI) we tested the small molecule tenovin-6 in zebrafish 
embryos The compound had been described previously by our group. The original aim of this study was to 
investigate if the activation of p53 in an organism could affect the ability of tumor cells to disseminate. Even 
though tenovin-6 did not activate wild-type p53 under the conditions tested, in vivo activity of the compound 
was still detectable, since embryos expressing mutant p53 (M214K) displayed an increase in p53 protein levels; 
furthermore, the compound was lethal in a dose- and time-dependent manner, and the embryos lost most of their 
brown/black pigmentation. The exact mechanism behind the latter observation could not be elucidated in the 
course of the project. However, tyrosinase, a key enzyme in melanogenesis, was not inhibited by tenovin-6, and 
the combination of data obtained by others on mutated or pharmacologically inhibited vacuolar H+-ATPase (V-
ATPase) and yeast mutant strains suggested that the compound may target V-ATPase.   
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1 INTRODUCTION 
1.1 CANCER 
Cancer is a collective term for all kinds of malignant tumors. The first cancer was described 
in the Edwin Smith Papyrus, which was written approximately 3000 BC (1). Tumorigenesis 
is considered to be a multistep process, in which several mutations must occur for a benign 
tumor to become malignant. This may also be the reason why the incidence rate of cancer 
increases with age (2). Hanahan and Weinberg defined six hallmarks of cancer in the year 
2000 (3), a list which was extended by four additional hallmarks about a decade later (4): 
Self-sufficiency in proliferative signals, insensitivity to anti-growth signals, tissue evasion 
and metastasis, limitless replicative potential, sustained angiogenesis, resistance to cell death, 
avoidance of immune destruction, induction of tumor-promoting inflammation, genome 
instability and mutation, and deregulation of cellular energetics (figure 1). 
 
 
 
 
 
 
 
 
 
Figure 1: The ten hallmarks of 
cancer. Adapted from Hanahan 
& Weinberg (4) in compliance 
with the conditions of the 
Elsevier user license. Copyright 
© 2011 Elsevier, Inc. 
 
1.1.1 Causes 
Cancer can be caused by a large number of factors, which can be both of genetic and 
environmental nature. In familial types of cancer, a mutation predisposing a person to cancer 
is being inherited. Usually, these people develop tumors early in life (5). In addition, cancer 
syndromes exist in which a factor is mutated that is involved in the development of various 
types of cancer. An example is the Li-Fraumeni syndrome, in which the tumor suppressor 
 8 
p53 is mutated. Subjects suffering from this syndrome often develop tumors early in life, in 
particular sarcomas, adrenocortical carcinomas, brain cancer and breast cancer (6).  
On the contrary, the exposure to environmental factors typically leads to cancer later in life. 
About 90-95% of all cancers can be attributed to environmental factors (7).These can be of 
various natures, e.g. chemical, physical or biological. A large number of both synthetic and 
natural compounds has been described that can cause various types of cancer (8, 9). UV light, 
X-rays and asbestos are examples of physical damage that can cause tumor formation (10). 
Chronic inflammation might exert a tumor-promoting effect by triggering constant cell 
renewal at the site of inflammation. This condition may amongst other things be caused by 
autoimmune diseases like inflammatory bowel disease or pathogens like Helicobacter pylori 
(11). Viral infections, e.g. with human papillomavirus (HPV), have also been shown to cause 
cancer (12). 
 
1.1.2 Current state of treatment possibilities  
Drugs interfering with the hallmarks of cancer have been developed. Some of them have 
already been approved, while others are still being tested in clinical trials (4, 13). Traditional 
chemotherapeutic drugs aim at killing cells that divide rapidly. These drugs can be 
categorized into DNA intercalators, DNA alkylating agents, topoisomerase inhibitors, 
tubulin-binding drugs or anti-metabolites (i.e. structural analogues of naturally occurring 
metabolites involved in DNA and RNA synthesis).  However, these drugs are not tumor-
specific. In addition, a large number of these drugs is genotoxic and can therefore introduce 
mutations in both healthy and tumor cells. Consequently, healthy cells can die, resulting in 
side effects like alopecia (hair loss), anemia, thrombocytopenia and leukopenia (followed by 
immunosuppression). Alternatively, normal cells can accumulate mutations and hence form 
new tumors (14). On the other side, when mutations are introduced in tumor cells, these cells 
can become more aggressive and form metastases (2), which is often lethal to the patient.  
More types of therapy exist. During radiotherapy, the affected area becomes exposed to 
ionizing radiation. However, as is the case for traditional chemotherapy, new mutations can 
be introduced and consequently lead to severe side effects, the formation of new tumors and 
more aggressive tumors. Surgery is an option in case a tumor is located where the removal of 
tissue would not be life-threatening, e.g in breast or prostate. Immunotherapy is an indirect 
and novel approach, during which immune cells are being activated to subsequently kill 
tumor cells. This can be achieved in several ways, e.g. by the use of cytokines or T-cell 
regulating antibodies (15-17). Targeted therapy is another novel approach that, in contrast to 
immunotherapy, aims at killing tumor cells directly. In this case, small molecules or 
antibodies are used that specifically target one protein or group of proteins (e.g. tyrosine 
kinase receptors). Examples are imatinib mesylate (Gleevec / Glivec), trastuzumab 
(Herceptin) and vemurafenib (Zelboraf) (18). It should be noted that therapies can be 
combined to achieve a more successful outcome (15, 17).  
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The success rates in oncology have been much lower compared with other fields, e.g. 
cardiovascular or infectious diseases (19). Currently, a major problem in curing patients is the 
resistance of cancer cells to therapy, which is often followed by relapse. It has been suggested 
that cancer stem cells, i.e. a fraction of cells that is supposed to drive tumor growth and 
progression, are responsible for this phenomenon. Targeting these cells is hence of particular 
interest (4, 20, 21). 
Thus, the development of new drugs is of great importance to find cures for patients suffering 
from all the various types of cancer. 
 
1.2 TUMOR SUPPRESSOR P53 
p53 was the first tumor suppressor to be identified (22-24), although during the first ten years 
after its discovery it was assumed to be an oncogene (25-27). Currently, it is the most-studied 
tumor suppressor, with more than 70,000 scientific articles mentioning it on PubMed (status: 
July 2014). Because of its central role in cancer, it has been designated as “The Guardian of 
the Genome” (28), “The Cellular Gatekeeper for Growth and Division” (29) and “The 
Policeman of the Oncogenes” (30). Even though it is mutated in over 50% of all cancers (22), 
the mutation prevalence varies a lot between different types of tumors (31). In most of those 
cases, in which p53 is not mutated, the protein is still impaired in its function through one of 
the following mechanisms:  
1) Negative regulators, in particular murine double minute 2 (MDM2) and murine 
double minute 4 (MDM4; also called MDMX), can be present at increased levels, e.g. 
due to gene amplification (32-34).  
2) The upstream positive regulator alternative reading frame (ARF / p14ARF) can be 
deleted or epigenetically inactivated (35). 
3) Certain viral proteins can inhibit or downregulate p53, such as the simian virus 40 
(SV40) large T antigen (23, 24), the adenovirus 5 E1b protein (36) and the E6 
proteins of HPV 16 and 18 (37, 38). 
More detailed information about p53 will be given in the following subchapters. 
 
1.2.1 The genetics of p53 
In this subchapter, the TP53 gene and the different isoforms it encodes are described. The 
protein domains mentioned here are further described in subsection 1.2.2. 
1.2.1.1 The TP53 gene 
The TP53 gene is evolutionarily conserved (39) and located on human chromosome 17p13. 1. 
It contains eleven exons, the first of which is noncoding (40). A number of single-nucleotide 
 10 
polymorphisms (SNPs) have been described in humans that affect p53 signaling in cells, 
resulting in differences in cancer risk and clinical outcome. The most studied SNP, 
designated rs1042522 in the Single Nucleotide Polymorphism Database (dbSNP) by the 
National Center for Biotechnology Information (NCBI), is located in codon 72. This SNP 
leads to a residue change from proline to arginine, which in turn affects the pro-apoptotic 
function of p53 (39, 41).  
 
Figure 2: The isoforms of p53. (A) The human TP53 gene structure. The TP53 gene comprises eleven exons 
and encodes twelve p53 isoforms using alternative promoters ( ), splicing sites (^) or translational initiation 
sites ( ). (B) Human p53 isoforms. Abbreviations: DBD, DNA-binding domain; kD, kilo Dalton; MW, 
molecular weight; NLS, nuclear localization signal; OD, oligomerization domain; PXXP, proline-rich 
domain; TAD, transactivation domain. Adapted from Surget et al. (40) in compliance with the conditions of 
the publisher’s license. Copyright © 2013 Dove Medical Press Limited. 
1.2.1.2 p53 isoforms 
The TP53 gene encodes at least twelve different p53 protein isoforms, which are the result of 
the usage of alternative promoters, initiation of translation at alternative start sites and 
alternative splicing as well as a combination thereof (figure 2) (40): 
1) To date, two promoters, P1 and P2, have been identified. The proximal promoter P1 is 
located in front of exon 1 and encodes all isoforms that contain a complete N-
terminus as well as the Δ40p53 isoforms, in which the first TAD is missing. The 
internal promoter P2 is situated in intron 4 and encodes all Δ133p53 and Δ160p53 
isoforms, which lack both transactivation domains (TADs) and the proline-rich 
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region; in addition, the Δ160p53 isoforms lack parts of the DNA binding domain 
(DBD).  
2) Four translation initiation sites have been described. The first one lies in exon 2 and 
initiates translation of all isoforms that contain the full-length N-terminus. The second 
site is in exon 4 and regulates the expression of the Δ40p53 isoforms. The remaining 
two translation initiation sites are situated in close proximity to each other in exon 5; 
translation of the Δ133p53 and Δ160p53 isoforms, respectively, starts from here.  
3) Alternative splicing can occur at four different sites in the p53 transcript. Alternative 
splicing between exons 2 and 3 determines if isoforms containing the full-length N-
terminus or Δ40p53 isoforms will be synthesized. The exclusion of intron 9 generates 
α isoforms, whereas partial retention thereof leads to generation of β and γ isoforms, 
respectively. The part of intron 9 that is included in the β isoforms is also called exon 
9b, and the part included in the γ isoforms is also called exon 9g. α isoforms contain 
an oligomerization domain (OD) and a negative-regulation domain, both of which are 
lacking in the β and γ isoforms due to the presence of a stop codon in both exon 9b 
and exon 9g.  
The canonical p53 protein (also named p53, full-length p53 (FLp53), p53α, or TAp53α) 
constitutes the most abundant isoform encoded by TP53. The different isoforms are 
expressed at different levels in both normal and tumor cells, and they can be expressed in 
different subcellular compartments. Furthermore, their functions can vary, i.e. they can 
inhibit or enhance p53 tumor-suppressor activity in a p53-(α) dependent and independent 
manner. For example, Δ40p53α has been shown to have dominant-negative effects, and 
Δ133p53α can promote tumor formation and aggressiveness in a p53(α)-dependent and -
independent manner. On the contrary, p53β can enhance p53 transcriptional activity, 
resulting in a higher rate of senescence and apoptosis (40).  
Importantly, cell lines, e.g. HCT116 and RKO, have been generated, in which p53 
supposedly was knocked out. “Knock-outs” were performed by replacing the first codon 
present in exon 2 with a resistance marker gene (42, 43). However, this modification 
resulted in a gene that still encodes all isoforms containing a truncated N-terminus, i.e. all 
Δ40p53, Δ133p53 and Δ160p53 isoforms. Indeed, expression of Δ40p53 protein has been 
detected in HCT116 p53-deficient cells (44). This should be borne in mind when using 
these cell lines.  
 
1.2.2 The functional domains of the p53 protein 
The canonical p53 protein is 393 aa long (45) and contains the domains described in the 
following subsections. Figure 3 illustrates the domains. It should be noted that the exact 
number of amino acid residues assigned to the different domains can vary depending on the 
source of information. 
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Figure 3: p53 protein domains. Numbers indicate amino acid residues. Orange bars indicate NLSs; the black bar 
shows where the NES is located. The protein and its domains are drawn to scale. Abbreviations: CRD, C-
terminal regulatory domain; DBD, DNA-binding domain; NLS, nuclear localization signal; OD, oligomerization 
domain; PRR, proline-rich domain; TAD, transactivation domain.  
1.2.2.1 Transactivation domain (TAD) 
The TAD, which is required for p53 to act as a transcription factor, is located at the N-
terminus. This domain can be further subdivided into TAD 1 at amino acids (aa) 1–40 and 
TAD2 at aa 41–61. The TAD is a binding site for a multitude of interacting proteins, such as 
components of the transcription machinery, the transcriptional co-activators p300/CBP 
(CREB-binding protein), and the negative regulators MDM2/MDM4 (45, 46). Despite the 
earlier assumption that TAD1 played a more important role in transactivation than TAD2 
(47), it has been shown that the transactivating function of p53 depends on four residues, each 
two of which are present in each TAD (46). 
1.2.2.2 Proline-rich domain (PRR) 
In close proximity to the TADs is a proline-rich domain (PRR) (aa 64–92), which contains 
five repeats of the aa sequence PXXP (where P represents proline and X any amino acid). It 
is involved in growth suppression and protein–protein interactions through binding to Src 
homology 3 domains (45, 48).  
1.2.2.3 DNA-binding domain (DBD) 
The DBD is located in the center of the protein (aa 94–292). It is crucial for p53 to function 
as a transcription factor, since it facilitates binding to response elements (REs). (49). Six 
mutation hotspots have been identified in the TP53 gene, and they are all located in this 
domain (31). All of these mutations result in the loss of p53 binding to REs and eventually 
altered target gene expression. Two of the mutants harboring hotspot mutations are so-called 
“contact mutants”. They have mutations at Arg-248 and Arg-273, which are residues that 
make direct contact to DNA. The other four hotspot mutants, i.e. Arg-175, Gly-245, Arg-249 
and Arg-282, are “conformational mutants” that have undergone a conformational change in 
the 3D structure of the DNA-binding surface and hence lose their ability to bind REs (50, 51). 
It should be noted, however, that mutant p53 can have pro-oncogenic functions (i.e. a gain-
of-function), which in part may be due to the binding of genes other than those targeted by wt 
p53 (46). 
1.2.2.4 Nuclear localization signals (NLSs) 
p53 contains three nuclear localization signals (NLSs) that facilitate translocation from the 
cytoplasm into the nucleus, a pre-requisite for p53 to become transcriptionally active. NLSI is 
located in closest proximity to the DBD, i.e. at aa 318-322, and is regarded as being the most 
  13 
essential NLS for nuclear import. NLSII (aa 378-382) and NLSIII (aa 386-390) are weaker 
than NLSI and contribute less to p53 nuclear import (52-54). 
1.2.2.5 Oligomerization domain (OD) 
p53 is most active as a tetramer. Its oligomerization domain (OD) facilitating tetramerization 
is located at aa 325–355. A leucine-rich nuclear export signal (NES) (aa 340-351) is located 
inside this domain. It facilitates export from the nucleus into the cytoplasm and is also 
required for tetramerization. Tetramer formation masks the NES and prevents access to the 
nuclear export machinery, which further enhances p53’s transcritional activity (55). 
1.2.2.6 C-terminal regulatory domain (CRD) 
Also the C-terminus of p53 has a regulatory function. Next to the nuclear localization signals 
NLSII and NLSIII mentioned above it contains residues that can be post-translationally 
modified. More information about this topic can be found in subsection 1.2.3. 
 
1.2.3 Post-translational modifications 
Various post-translational modifications have been described in connection with the p53 
protein. It can be phosphorylated, ubiquitinated, neddylated, sumoylated, acetylated and 
methylated (figure 4) (56). Phosphorylation and acetylation generally activate p53, whereas 
ubiquitination targets p53 for nuclear export and degradation by the proteasome.  
 
Figure 4: Post-translational modifications of p53. Amino acid residues that can be post-translationally modified 
are each indicated on top of the corresponding bar. A selection of enzymes catalyzing these modifications are 
shown on the right. Please refer to figure 5 for an updated version of the sites that can be acetylated. Adapted 
from Dai & Gu (56) with permission from the publisher. Copyright © 2010 Elsevier, Inc. 
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1.2.3.1 Phosphorylation 
Phosphorylation was the first post-translational modification of p53 to be identified (57). A 
number of serine and threonine residues, which are mainly located at the N-terminus, can be 
phosphorylated by several kinases, including ATM/ATR/DNAPK and Chk1/Chk2, that 
become activated upon DNA damage. In particular, phosphorylation at Ser-15 and Ser-20 has 
been studied extensively. Phosphorylation at these residues stabilizes p53 by disrupting its 
interaction with MDM2 and promotes the recruitment of transcriptional coactivators (56, 58).  
1.2.3.2 Ubiquitination 
During the process of ubiquitination, either one or more ubiquitin molecules, about ~8 kDa in 
size, are conjugated to lysine residues of a target protein. An E1 ubiquitin-activating enzyme, 
an E2 ubiquitin-conjugating enzyme and an E3 ubiquitin-ligating enzyme are required for this 
process. Ubiquitination has been detected at eleven lysine residues at the C-terminus of p53, 
six of which (i.e. Lys-370, Lys-372, Lys-373, Lys-381, Lys-382 and Lys-386) can be 
ubiquitinated by MDM2. The latter is the principal E3 ubiquitin-ligase for p53 next to 
approximately 20 other E3 ubiquitin-ligases. MDM2 can catalyze both multi-mono- and 
polyubiquitination. Multi-monoubiquitination, i.e. the simultaneous monoubiquitination of 
several lysine residues, results in inhibition of acetylation of p53, which is crucial for p53 to 
function normally, as well as nuclear export of p53. Polyubiquitination leads to proteasomal 
degradation of p53. Next to ubiquitinases, a comparatively small number of deubiquitinases 
(DUBs) have been identified. They aid in stabilizing the p53 protein and removal of the 
ubiquitin tag for nuclear export (56, 59). 
1.2.3.3 Neddylation 
A ubiquitin-like protein called neural precursor cell expressed developmentally 
downregulated protein 8 (NEDD8) can be conjugated to p53 as well. It resembles ubiquitin in 
both its 3D structure and its mechanism of conjugation through lysines. MDM2 can neddylate 
p53 at residues Lys-370, Lys-372 and Lys-373, whereas F-box protein 11 (FBXO11) 
neddylates Lys-320 and Lys-321. In contrast to ubiquitination, neddylation does not induce 
changes in p53 localization or stability, but it affects its transactivational activity (56, 58). 
1.2.3.4 Sumoylation 
Small ubiquitin-like modifier (SUMO) is another ubiquitin-like protein. Only one residue, i.e. 
Lys-386, has been identified to date that can be sumoylated. Enzymes facilitating 
sumoylation of p53 are sumoylated by members of the protein inhibitor of activated stat 
(PIAS) family and topoisomerase I binding, arginine/serine-rich, E3-ubiquitin protein ligase 
(Topors). The function of sumoylation is unclear. Both promotion and inhibition of p53 
transcriptional activity as well as translocation of p53 to the cytoplasm have been suggested 
(56, 58, 59) 
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1.2.3.5 Acetylation 
During the process of acetylation, acetyl groups are enzymatically placed onto the ε-amino 
group of lysine residues of target proteins. p53 was the first non-histone substrate shown to 
be acetylated by histone acetyl transferases (HATs) (60, 61). Acetylation occurs in response 
to cellular stress, e.g. DNA damage, and leads to stabilization and activation of p53 as well as 
recruitment of transcriptional cofactors. 13 lysine residues can be acetylated in the p53 
protein (figure 5), three of which are located in the DBD (Lys-120, Lys-164 and Lys-292), 
one in the linker region between DBD and OD (Lys-305), three in the OD (Lys-320, Lys-351 
and Lys-357) and the remaining six in the CRD (Lys-370, Lys-372, Lys-373, Lys-381, Lys-
382 and Lys-386).  
 
Figure 5: Acetylation sites of p53. Acetylation sites are indicated by yellow bars and the respective aa residue 
number within the p53 protein. Abbreviations: CRD, C-terminal regulatory domain; DBD, DNA-binding 
domain; K, lysine; OD, oligomerization domain; PRR, proline-rich domain; TAD, transactivation domain. 
Adapted from Wagner et al. (62) with permission from the publisher. Copyright © 2014 Elsevier, Inc. 
 
The HATs p300 and CREB-binding protein (CBP) acetylate p53 at positions 164, 305, 370, 
372, 373, 381, 382 and 386; the HAT p300/CBP-associated factor (PCAF) acetylates p53 at 
Lys-320. Human males-absent-on-the-first (hMOF) and tat-interactive protein of 60 kDa 
(TIP60) can acetylate p53 at Lys-120. Ac-Lys-120 was shown to be critical for induction of 
apoptosis, but to have no effect on DNA binding and protein stability (56, 61-63). 
Simultaneous acetylation of eight lysine residues, i.e. Lys-120, Lys-164, Lys-370, Lys-372, 
Lys-373, v381, Lys-382 and Lys-386, was shown to be required for interruption of the 
physical interaction between p53 and MDM2 at target gene promoters. This is a pre-requisite 
for p53 to activate transcription of the pro-apoptotic genes BAX, p53 up-regulated modulator 
of apoptosis (PUMA) and p53-inducible gene 3 (PIG3). Furthermore, when these eight 
residues are acetylated, phosphorylation of p53 becomes dispensable for transcription of 
these target genes upon treatment with the DNA damage-inducing compound actinomycin D 
(actD). Interruption of the MDM2-p53 interaction by mutation of the above-mentioned eight 
lysine residues also abolished p21 expression (64). However, in contrast to pro-apoptotic 
proteins, p21 can be expressed at lower levels in the presence of MDM2-p53 complexes, 
suggesting that its transcription is less sensitive to the physical interaction between p53 and 
MDM2. Interestingly, transcription of the MDM2 gene was shown to be unaffected by the 
binding of MDM2 to p53 (58, 61). 
Acetylation is a reversible process. Acetyl-groups can be removed by histone deacetylases 
(HDACs), a more detailed description of which will follow in chapter 3. HDAC1 present in a 
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protein complex was shown to deacetylate p53. HDAC1 may not be able to directly interact 
with p53, but might depend on other proteins to reach it (65). Also HDAC2 has been shown 
to deacetylate p53, i.e. at residues Lys-320, Lys-373 and Lys-382. Which residues are 
targeted might be cell-type specific, though (62). In addition, the class III HDACs sirtuin 1 
(SirT1) and SirT2 have been shown to deacetylate p53 at Lys-382 (66-69). 
1.2.3.6 Methylation 
p53 can be methylated at arginine and lysine residues at its C-terminus. A number of 
methyltransferases have been described that can mono- or dimethylate p53. Protein arginine 
N-methyl transferase 5 (PRMT5) interacts with p53 via the protein Strap and methylates Arg-
333, Arg-335 and Arg-337. Methylation of these residues might be required for p21 
transcription and a subsequent induction of cell cycle arrest (70). Smyd2 and Set8/PR-Set7 
monomethylate p53 at K370 and K382, respectively, which leads to repression of p53 
activity. Set7/9 monomethylate p53 at Lys-372, which facilitates acetylation of p53 by Tip60 
and prevents methylation of K370 by Smyd2; therefore, monomethylation of Lys-372 results 
in enhanced p53 activity (71, 72). In addition, p53 can be dimethylated on Lys-370 and Lys-
382, which facilitates its interaction with p53-binding protein 1 (53BP1), an important 
mediator of the DNA damage response (DDR) upon occurrence of DNA double-strand 
breaks (DSBs) (73, 74). Demethylation of Lys-370me2 to Lys-370me1 by lysine specific 
demethylase 1 (LSD1) represses p53 function through the inhibition of the interaction 
between p53 and 53BP1 (56, 74). 
 
1.2.4 The p53 pathway 
p53 can be activated by various types of stress, e.g. DNA damage, oncogene activation, 
nutrient deprivation, ribonucleotide depletion, telomerase shortening or hypoxia (figure 6) 
(27). Once activated, it mainly acts as a transcription factor. In addition, p53 has been shown 
to induce cell death via non-transcriptional mechanisms (75):  
1) It can promote translocation of the pro-apoptotic protein Bax from the cytoplasm to 
mitochondria. In turn, Bax forms pores in the mitochondrial outer membrane, which 
results in cytochrome c release and eventually apoptosis. 
2) It can facilitate the release of the pro-apoptotic protein Bak from inhibitors in the 
mitochondrial outer membrane to facilitate pore formation and subsequent 
cytochrome c release, which results in apoptosis.  
3) p53 can induce necrosis upon reactive oxygen species (ROS) formation.  
p53 has a large number of transcriptional targets, through which it exerts its effects like cell 
cycle arrest, apoptosis, DNA repair, senescence or the induction of an anti-oxidant response 
(27). Important target genes and key players in the p53 pathway are described in the 
following subsections. 
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Figure 6: Regulation and 
action of p53.  
 
1.2.4.1 CDKN1A (p21) 
p21 is also known as wild-type p53-activated fragment 1 (Waf1), cyclin-dependent kinase-
interacting protein 1 (Cip1), senescent cell-derived growth inhibitor 1 (SDI1), melanoma-
derived antigen 6 (MDA6) and cyclin-dependent kinase inhibitor 1 A (CDKN1A), and is 
encoded by the CDKN1A gene. p21 has many functions, the most studied of which is it 
ability to inhibit cyclin-dependent kinases (cdks), in particular cdk1 and cdk2, and their 
interaction with cyclins. This inhibition eventually leads to cell cycle arrest and/or senescence 
(76). 
1.2.4.2 Pro-apoptotic genes 
Target genes like BAX, PUMA, PIG3, NOXA, FAS (also known as e.g. CD95) and death-
receptor 5 (DR5; also known as e.g. KILLER or TRAILR2) encode proteins that exert pro-
apoptotic functions (22).  
1.2.4.3 MDM2  
MDM2 encodes the main negative regulator of p53. In humans, it is called HDM2.As 
mentioned in subsection 1.2.3.2, it is an E3-ubiquitin ligase that can both multi-mono- and 
polyubiquitinate p53. Crystallographic data showed that the N-terminal domain of MDM2 
forms a deep hydrophobic cleft into which the TAD (aa 18-23) of p53 binds (77-79). This 
physical interaction interferes with p53’s transactivational abilities (33, 61, 77, 80). 
1.2.4.4 MDMX 
The MDMX gene (also called MDM4; HDMX in humans) can be transcribed from two 
promoters, i.e. the constitutive P1 promoter and the alternative P2 promoter. The latter gives 
rise to a protein that has a longer N-terminus than its constitutively expressed counterpart and 
is called HDMX-L (“L” standing for “long”). p53 can only transactivate transcription of 
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HDMX-L and does so only under certain circumstances (81). In general, MDM4 is thought to 
play a dual role in p53 regulation. It can form heterodimers with its homolog MDM2 via its 
RING domain and, depending on its abundance, it can subsequently enhance or decrease the 
ubiquitin-ligase function of MDM2 (33). 
1.2.4.5 p14ARF 
p14ARF (called p19ARF in mice) is one of the three products of the INK4b-ARF-INK4a locus, 
also called CDKN2A, that encodes p15INK4B, p14ARF and p16INK4a. Due to alternative splicing 
the open reading frames (ORFs) differ between the two possible transcripts, eventually 
resulting in one of the protein products. p14ARF becomes induced upon activation of certain 
oncogenes, e.g. myc, upon which it exerts its function as an MDM2 inhibitor (82, 83). p14ARF 
can physically interact with MDM2 (84). The literature suggests that this can lead to either 
MDM2 degradation or stabilization (84, 85). Furthermore, this binding may lead to inhibition 
of MDM2’s ubiquitin-ligase activity on p53 as well as sequestration of MDM2 in the 
nucleolus, where p14ARF is mainly located. Furthermore, p14ARF may inhibit the export of 
p53/mdm2 complexes from the nucleus (86-88). Next to MDM2, p14ARF can inhibit ARF-
binding protein 1 (ARF-BP1; also known as Mcl-1 ubiquitin ligase E3 (Mule)). Like MDM2, 
ARF-BP1 acts as specific E3 ubiquitin- ligase for p53. However, ARF-BP1 may not be 
transcriptionally regulated by p53 (89). Thus, p14ARF can increase p53 levels through the 
inhibition of at least two negative regulators. Interestingly, p53 negatively regulates p14ARF 
expression (85), which contributes to the negative feedback loop of p53 (figure 6).  
 
1.2.5 Pharmacological reactivation of wt p53 
p53 is mutated in over 50% of all cancers, and in the remaining cases it is usually inactive 
due to overexpression of MDM2 or MDMX (32-34), deletion or epigenetic silencing of 
p14ARF (35) or the presence of viral proteins (23, 24, 36-38). Reactivation of p53’s tumor-
suppressive function in cancer has been approached by many scientists in academia and 
industry. Several strategies have been developed to reactivate wt p53, such as inhibition of 
the interaction between p53 and its negative regulators MDM2 and MDMX or inhibition of 
other factors that directly or indirectly affect p53 activity. Also strategies for reactivation in 
tumors expressing mutant p53 have been established, such as p53 gene therapies and 
restoration of the 3D structure of conformational p53 mutants (90). Since the studies 
presented in this thesis focus on pharmacological reactivation of wt p53, the following 
subsections will highlight this topic. 
1.2.5.1 Inhibition of MDM2/MDMX-p53 interactions via binding to p53 
p53 interacts with MDM2 and MDMX via its TAD. Only one small molecule, called 
reactivation of p53 and induction of tumor cell apoptosis (RITA), has been described so far 
that reactivates wt p53 by interruption of MDM2-p53 and MDMX-p53 interactions through 
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direct binding to p53. The compound induces apoptosis in tumor cells, but not in normal cells 
(91, 92), which is the desirable effect in cancer therapy.  
1.2.5.2 Inhibition of MDM2-p53 interactions via binding to MDM2 
A number of compounds have been identified that interfere with the interaction of MDM2 
and p53 by competitive binding to MDM2. Some of these are structural analogs, e.g. nutlin-3, 
RG7112 (RO5045337) and RG7388 (RO5503781); RO-2443 and RO-5963; and MI-219, 
MI-773 (SAR405838) and MI-888 (90). In addition, new compounds (RO2468, RO5353 and 
RO8994) have recently been designed by combining functionally and pharmacokinetically 
important chemical groups of RG7388 and MI-888 in one molecule (93, 94). Nutlins were 
the first small-molecule inhibitors of the p53–MDM2 interaction to be identified, with nutlin-
3a being the most potent structural analog amongst those tested in the initial study, which was 
published ten years ago (95). Following up on that trend, the nutlin analog RG7112 was the 
first inhibitor of p53–MDM2 binding being tested in clinical trials (96). Since then, also 
RG7388, MI-773 and DS‑3032b have entered phase I clinical trials (90). It should be noted, 
however, that nutlins have a pro-apoptotic response in some tumor types, whereas in others 
they induce cell cycle arrest (90). The latter is an undesired effect in the treatment of cancer, 
since relapse may occur after termination of the therapy. Careful choice of patients and 
further studies will therefore be required. 
1.2.5.3 Inhibition of p53-MDM2/MDMX interactions by binding to MDM2 and/or MDMX 
RO-2443 and its more water-soluble structural analog RO-5963 do not only bind to MDM2, 
but also MDMX with high affinity. This has been shown to be of great advantage in those 
tumors that express high levels of MDMX, since these can be resistant to compounds that 
target MDM2 only (like nutlins and compounds from the MI series). RO-2443 and RO-5963 
homo- and/or heterodimerize MDM2 and MDMX proteins, thereby preventing both of them 
from interacting with p53. This leads to p53 activation and eventually cell cycle arrest and 
cell death (97).  
Stapled peptides are a new class of molecules that entered the p53 field less than five years 
ago. Several stapled peptides have been developed to inhibit p53-MDM binding. 
Interestingly, most stapled peptides developed in this context so far have been shown to 
inhibit both MDM2 and MDMX, suggesting that resistance to these molecules due to 
elevated MDMX levels may not be a problem (90).  
1.2.5.4 Other approaches of p53 reactivation 
Since p53 can be regulated by a large number of upstream factors and events to fulfill its 
function as a tumor suppressor, there are a many additional ways to reactivate it. A few 
examples are the following ones: 
1) As mentioned in subsection 1.2.3.5, the sirtuins SirT1 and SirT2 can deacetylate p53 
at Lys-382, which leads to inactivation of the protein (66-69). Sirtuin inhibitors, e.g. 
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tenovin-6, salermide or sirtinol, can activate p53 by simultaneous inhibition of SirT1 
and SirT2 (68, 98).  
2) Roscovitine can, next to its CDK-inhibitory function, reduce MDM2 levels inside 
cells, which in turn activates p53 (99).  
3) ActD has also been shown to induce p53. At low doses (i.e. ≤ 20 nM) (LDactD) it 
does not induce DSBs and induces p53 by inhibition of RNA polymerases by DNA 
intercalation in guanosine-rich regions (100-102). Ribosomal DNA is particularly rich 
in guanosine, and hence a decrease in rRNA levels upon inhibition of RNA 
polymerases I and/or III by LDactD may lead to increased levels of free ribosomal 
proteins, such as L11. The latter inhibits MDM2 (101-103). Further, inhibition of 
RNA polymerase II by LDactD followed by a decrease in mRNA levels has been 
described to activate p53 (101). 
4) p53 becomes exported from the nucleus by exportin-1 (XPO1; also called 
chromosome region maintenance 1 (CRM1)), which binds to the NES at the p53 C-
terminus. Inhibition of XPO1 by leptomycin B (LMB) or the compounds KPT-185, 
KPT-276 and KPT-330, respectively, leads to accumulation of p53 in the nucleus 
where it acts as a trancription factor. However, both leptomycin B and the KPT 
compounds were shown to have a strong cytostatic effect, which may be undesirable 
in cancer therapy (104-106).   
1.2.5.5 Cyclotherapy 
Chemotherapeutic drugs like tubulin poisons and DNA damaging compounds are widely 
used in the clinic to treat cancer. However, since they target any type of cell that divides 
frequently, side effects like alopecia, anemia, thrombocytopenia, leucopenia and the 
formation of new tumors as well as further dedifferentiation of existing tumor cells are often 
the consequence (14). The concept of p53-dependent cyclotherapy was first suggested by 
David P. Lane in 1992 (28), but it took about another 20 years, until it was tested in cell 
culture for the first time (107) and the term “cyclotherapy” was coined (108). During 
cyclotherapy, patients carrying p53-mutant tumors would initially be treated with a non-
genotoxic drug that activates wt p53 and primarily has a cytostatic effect. Since the tumors 
would express mutant p53, only the patients’ healthy cells would react to this drug. 
Afterwards, a second drug that has a p53-independent cytotoxic effect would be given to the 
patients, such as a classical chemotherapeutic agent. Since these drugs primarily kill dividing 
cells, only tumor cells would be affected. After tumor clearance, drug treatment would be 
terminated. Healthy cells would have survived and would recover from potential temporary 
damage caused by the p53-activating drug (figure 7) (109, 110). 
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 Figure 7: The concept of cyclotherapy. 
Several drug combinations have been tested in this context in cell culture (109, 110). A 
xenograft study showed that neutropenia caused by the polo-like kinase 1 (PLK1) inhibitor 
BI-2536 could be prevented, if mice were co-treated with nutlin-3 (43). This may be the only 
study that suggests that the cyclotherapy concept could work in vivo. Thus, further in vivo 
studies will be required for cyclotherapy to be tested in clinical trials. Furthermore, the 
majority of the cytostatic compounds that have been tested in cell culture in a cyclotherapy 
context have not been clinically approved yet. Some possible candidates are currently being 
tested in phase I clinical trials, e.g. RG7112, RG7388, MI-773 and DS-3032b, whereas 
others, like tenovin-6, have not reached this stage yet. Thus, time will tell if cyclotherapy 
eventually will enter the clinic.  
1.2.5.6 Cell-based assay to screen for activators of wt p53 
Several screens using a cell-based assay have been performed in Sonia Laín’s laboratory to 
identify small molecules that can reactivate wt p53. Structural analogs or the actual hit 
compounds identified via these screens form the basis of five out of six studies presented in 
this thesis, i.e. tenovin-6 (papers I and IV), tenovin-D3 (paper II), MJ05 (paper IV) and 
MJ25 (paper VI). The cell-based assay used for screening purposes was developed by 
Frebourg and colleagues in 1992 and was originally intended as a method for the 
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identification of germline mutations that lead to transcriptional inactivation of p53 (111). In 
2005, Berkson and colleagues were the first ones who applied this assay for the purpose of 
screening small molecules to identify wt p53 reactivators (112).  
 
Figure 8: Cell-based reporter assay for the determination of p53 activity. (A) The reporter construct 
pRGCΔFosLacZ contains the following elements: Two p53 response elements (REs) derived from the ribosomal 
gene cluster (RGC) in a head-to-head orientation, a promoter containing a TATA box derived from a truncated 
promoter of the murine fos gene, the open reading frame (ORF) of the LacZ gene encoding β-galactosidase, an 
intron derived from the SV40 small-t antigen and the SV40 polyadenylation signal (polyA). (B) p53 activity can 
be measured by detection of chlorophenol red, a red chromophore produced by β-galactosidase (β-gal) in the 
presence of chlorophenol red-β-D-galactopyranoside (CPRG). (C) Illustration of the assay in 96-well format. A 
yellow-to-magenta gradient is proportional to the presence of chlorophenol red and hence an indirect indicator of 
p53 activity. Panel C was adapted from van Leeuwen and colleagues (113) in compliance with the conditions of 
the publisher’s license. 
 
Two cell lines, i.e. the murine prostate-derived cell line T22 (112, 114) and the human 
melanoma cell line ARN8 (115) (a subclone derived from the A375 cell line), have been 
generated by stable transfection with the plasmid pRGCΔFosLacZ (figure 8A). This plasmid 
contains two copies of the p53-binding site in the ribosomal gene cluster (RGC) in a head-to-
head orientation (116), which was cloned upstream of a deletion mutant of the murine fos 
promoter. The latter consists of a fragment that includes 56 base pairs (bp) located upstream 
of the transcription start site of the fos gene; this fragment contains a TATA box, but is 
devoid of other regulatory elements (REs) (117). The Δfos promoter is followed by the ORF 
of the LacZ gene (encoding β-galactosidase), the SV40 small-t antigen intron, which may 
increase the efficiency of transcription and the stability of the mRNA product, and the 
polyadenylation signals of SV40 (111).  
T22 and/or ARN8 cells are treated with compound of interest, e.g. small molecules derived 
from chemical libraries as in Sonia Laín’s screens, for the desired period of time (e.g. 
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overnight). Afterwards, they are lysed and a substrate of β-galactosidase, i.e. chlorophenol 
red-β-D-galactopyranoside (CPRG), is added to the lysates. CPRG is yellow in color and 
becomes converted to β-galactose and chlorophenol red (figures 8B and 8C). The latter is a 
red chromophore that can be quanitified spectrophotometrically, e.g. with a microplate 
reader. 
 
1.3 HISTONE DEACETYLASES 
Histone deacetylases (HDACs) were identified due to their ability to deacetylate acetyl-lysine 
(Ac-K / Ac-Lys) residues in histones, but are nowadays sometimes referred to as KDACs due 
to their ability to target Ac-Lys in non-histone proteins (figure 9). The first mammalian 
HDAC (HDAC1, back then called HD1) was identified in 1996 (118) and since then 17 
additional HDACs have been identified (119). 
 
Figure 9: Deacetylation of lysine residues present in histones and non-histone proteins by histone deacetylases 
(HDACs). An acetyl group present at the ε-amino group of a lysine residue is removed in the presence of water 
(H2O) and an HDAC, resulting in the formation of an acetate molecule and lysine. Adapted from Barneda-
Zahonero & Parra (119) in compliance with the conditions of the Elsevier user license. Copyright © 2012 
Elsevier, Inc. 
 
1.3.1 Classification 
HDACs have been classified according to their homology with yeast proteins (119):  
 Class I HDACs, i.e. HDAC1, HDAC2, HDAC3 and HDAC8, are highly homologous 
to the yeast transcriptional regulator Rpd3p. They are ubiquitously expressed in all 
tissues. 
 Class II HDACs, i.e. HDAC4, HDAC5, HDAC6, HDAC7, HDAC9 and HDAC10, 
are homologs of Hda1. This class can be further subdivided into class IIa (HDAC4, 
HDAC5, HDAC7 and HDAC9) and class IIb (HDAC6 and HDAC10) based on 
similarities and differences in their protein structure. Class II HDACs are expressed in 
a tissue-specific manner.  
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 Class III is comprised of the sirtuins, i.e. SirT1 to SirT7, and they are homologous to 
silencing information regulator 2 (SIR2). Their expression is not restricted to certain 
tissues, but their subcellular localization can differ (see below). 
 Class IV consists of HDAC11, the catalytic core region of which is homologous to 
that in class I and II HDACs. This HDAC is also expressed in a tissue-specific 
manner (120). 
1.3.1.1 “Classical” HDACs 
Class I, II and IV HDACs are also referred to as “classical” HDACs and they are Zn2+-
dependent. They exert partially overlapping and partially individual functions. Overall, 
HDACs are considered to be able to deacetylate histones, which results in chromatin 
condensation (i.e. the formation of heterochromatin) and therefore a decreased access of 
transcription factors to their target genes. Depending on their individual target proteins and 
expression in different tissues, HDACs can be involved in the regulation of proliferation, 
apoptosis, DNA damage responses and cell differentiation as well as the development and 
physiology of organisms (119). 
1.3.1.2 Sirtuins 
Sirtuins, on the other hand, are dependent on the cofactor NAD+ for their catalytic action. 
They can act as deacetylases (SirT1, SirT2, SirT3 and SirT5) or ADP-ribosyltransferases 
(SirT4 and SirT6), although none of these functions has been assigned to SirT7, which has 
been shown to regulate rRNA transcription by RNA polymerase I through a yet unknown 
mechanism (121). Due to their NAD+ dependence, sirtuins have been linked to metabolism. 
Indeed, they sense the cell’s energy and redox status. They can deacetylate metabolic 
enzymes, regulate metabolic gene transcription, regulate autophagy and, besides, regulate 
DNA repair (122). The subcellular localization varies between the different sirtuins. SirT1, 
SirT6 and SirT7 are primarily localized in the nucleus, with SirT1 being present in the 
nucleoplasm, SirT6 being associated with heterochromatin and SirT7 with nucleoli; SirT2 is 
mainly present in the cytoplasm, and SirT3, SirT4 and SirT5 in mitochondria (121, 123). 
However, the precise subcellular localization may vary in different cell types and upon 
changes in stress and molecular interactions. In particular, SirT1 and SirT2 have been shown 
to shuttle back and forth between nucleus and cytoplasm where they interact with different 
proteins (124). Despite the ability of SIR2 or its respective ortholog to increase lifespan in 
yeast (S. cerevisiae), worm (C. elegans) and fruit fly (Drosophila) (124), overexpression of 
single sirtuins did not have that effect in cultured HNDFs or prostate epithelial cells (123). 
Nevertheless, sirtuins have been shown to play a role in several ageing-related diseases, such 
as type II diabetes mellitus, a number of neurodegenerative diseases, cancer and 
cardiovascular disease, and also in inflammation and the infection with human 
immunodeficiency virus (HIV) (124).  
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1.3.2 HDAC inhibitors 
A large number of HDAC inhibitors (HDACis) have been characterized that are derived from 
both natural and chemical sources. Some of them are pan-HADCis, targeting several HDACs 
at the same time, whereas others are highly specific (125). An example of a specific HDACi 
is the chemically synthesized small molecule tubacin, which targets HDAC6 and thereby 
promotes acetylation of α-tubulin (126). A widely used pan-HDACi is trichostatin A (TSA), a 
natural compound produced by several strains of the Actinobacteria genus Streptomyces 
(127). TSA targets classical HDACs except for those of class IIa with an IC50 in the 
nanomolar range (128). In general, HDACis can be subdivided based on their chemical 
structure as follows (125): 
1) Hydroxamic acids, e.g. TSA, M-344, suberoylanilide hydroxamic acid (SAHA; 
also known as vorinostat or Zolinza), PXD101 (belinostat; also called Beleodaq), 
LBH589 (panobinostat) and PCI-24781 (abexinostat hydrochloride)  
2) Aliphatic acids, including valproic acid (VPA), butyric acid and phenylbutyric 
acid 
3) Benzamides, including MS-275 (entinostat) and MGCD0103 (mocetinostat) 
4) Tetrapeptides/depsipeptides, including apicidin and FK228 (FR901228, 
depsipeptide, romidepsin, Istodax) 
5) Sirtuin inhibitors, such as the pan-inhibitor nicotinamide and the specific SirT1 
and SirT2 inhibitors tenovin-6, sirtinol, cambinol and EX-527. 
1.3.2.1 Clinically approved HDACis 
So far, the following three HDACis have been approved by the U. S. Food and Drug 
Administration (FDA):  
1) The first HDACi to be clinically approved was SAHA (vorinostat, Zolinza), 
namely in October 2006 for the treatment of cutaneous manifestations of 
cutaneous T-cell lymphoma (CTCL) in patients with progressive, persistent, or 
recurrent disease on or following two systemic therapies (129). 
2) In November 2009, romidepsin (Istodax) was approved for the treatment of CTCL 
in patients who have received at least one prior systemic therapy. In addition, the 
drug was approved in June 2011 for the treatment of peripheral T-cell lymphoma 
(PTCL) in patients who have received at least one prior therapy (130). 
3) Very recently, on 3rd July 2014, the FDA granted accelerated approval to 
belinostat (Beleodaq) for the treatment of patients with relapsed or refractory 
PTCL (131). 
1.3.2.2 Improvement of cellular reprogramming efficiency by HDACis 
Next to the use as therapeutic drugs, HDACis have been used in another context, i.e. the 
generation of induced pluripotent stem cells (iPSCs). The classical pan-HDACis SAHA and 
in particular TSA and VPA were shown to promote reprogramming efficiency during iPSC 
 26 
generation (132). The mechanism of action has been attributed to their broad effect on 
HDACs, although we propose a model (paper III) suggesting that repression of p53 activity 
by TSA, in particular with regards to p21 expression, may contribute to a decreased 
frequency of senescence, which is a limiting event during the generation of iPSCs (132, 133).  
 
1.4 THE THIOREDOXIN SYSTEM 
The thioredoxin (Trx) system consists of Trx, the selenoprotein thioredoxin reductase (TrxR) 
as well as nicotinamide adenine dinucleotide phosphate (NADPH). The system is involved in 
the regulation of redox signaling and maintenance of a balanced cellular redox status, thereby 
protecting cells from oxidative stress caused by ROS and consequently from cell death. 
Furthermore, it can protect cells from nitrosative stress caused by reactive nitrogen species 
(134, 135). Trx and TrxR can be either in an oxidized (Trxox / TrxRox) or reduced state (Trxred 
/ TrxRred). NADPH+H+, which are formed during the pentose phosphate pathway, can reduce 
a disulfide group in TrxRox, resulting in TrxRred. In turn, the latter can reduce a disulfide 
present in the active site of Trxox to a dithiol (resulting in Trxred), thereby activating the latter 
(figure 10) (136).  
 
Figure 10: The Trx system and the regulation of the oxidation status of its components. Abbreviations: NADPH, 
nicotinamide adenine dinucleotide phosphate; ox, oxidized; red, reduced; Trx, thioredoxin; TrxR, thioredoxin 
reductase. Adapted from Lee et al. (136) with permission from the publisher. Copyright © 2013, Mary Ann 
Liebert, Inc. 
 
1.4.1 Target proteins and functions 
Trxred can reduce a large number of target protein. A few examples are given below (134, 
136). 
1) Reductive enzymes such as peroxiredoxin (Prx), ribonucleotide reductase (RNR) and 
methionine sulfoxide reductase (Msr), which in turn catalyze the reduction of 
peroxides, ribonucleotides, and methionine sulfoxides, respectively.  
2) Redox-sensitive molecules, including apoptosis signal-regulated kinase 1 (ASK1), 
thioredoxin-interacting protein (TXNIP) and phosphatase and tensin homolog 
(PTEN).  
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3) Redox-regulated transcription factors which  contain redox-sensitive cysteines in their 
DNA binding domain, e.g. activator protein 1 (AP-1), nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-κB), p21, p53, hypoxia-inducible 
transcription factor-1 alpha (HIF-1α), the glucocorticoid receptor, the estrogen 
receptor, NF-E2-related factor 2 (Nrf2), octamer-binding transcription factor 4 (Oct-
4), and transcription factor IIIC-gamma subunit (TFIIIC). 
Due to its large spectrum of targets, Trx is involved in the regulation of many processes on 
the cellular and organismal level, such as proliferation, apoptosis, cell migration, 
inflammation and immune function, metabolism, development and neuroprotection. 
Furthermore, dysregulation of the Trx system can result in various diseases and disorders, 
such as cardiovascular diseases, inflammation, metabolic syndrome, type 1 and 2 diabetes 
mellitus, neurodegenerative diseases, arthritis and cancer (134, 136, 137).  
 
1.4.2 Isoforms of Trx and TrxR 
Four isoforms of Trx encoded by three separate genes have been identified in humans (134, 
136): 
1) Trx1, which is primarily located in the cytoplasm, but can be translocated into the 
nucleus as well as secreted from the cell under certain circumstances. 
2) Trx2, which is located in mitochondria. 
3) Trx3 is localized in the Golgi apparatus of spermatocytes and spermatids; hence it is 
also called SpTrx. 
4) A truncated form of Trx1 (Trx80) is formed upon cleavage of Trx1 by α-secretase. 
This isoform lacks oxidoreductive properties and is not reduced by Trx reductase. It 
can prevent the aggregation of β-amyloid, thereby reducing toxicity caused by the 
latter.  
The following isoforms of the selenoprotein TrxR have been described, which are encoded by 
three separate genes: 
1) TrxR1, which is located in the cytoplasm. Its pre-mRNA can undergo alternative 
splicing at the 5’-end, resulting in two additional isoforms. 
2) TrxR2, which is located in mitochondria. Two additional isoforms of TrxR2 can be 
formed by alternatively splicing, and these isoforms are cytosolic.  
3) TrxR3, also called Trx glutathione (GSH) reductase, which is primarily expressed in 
male germ cells. 
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1.4.3 Inhibitors of Trx and TrxR 
1.4.3.1 Trx inhibitor TXNIP 
TXNIP is an endogenous inhibitor of Trx1 and Trx2. It is also called human Trx-binding 
protein-2 (TBP-2) and vitamin D3-upregulated protein 1 (VDUP1). It interacts with the 
active center of Trx1, which leads to inhibition of the reducing activity of the latter (137). 
1.4.3.2 TrxR inhibitors 
TrxR is contains a selenocystein (i.e. the 21st “naturally occurring” amino acid in the genetic 
code) in its C-terminus, which makes it easily accessible to electrophilic compounds (135, 
138). A large number of TrxR inhibitors has been identified and can be subdivided into the 
following four classes (135): 
1) Type I, comprising metal or metalloid containing compounds, e.g. auranofin, 
cisplatin, arsenic trioxide or lead ions.  
2) Type II are Michael acceptors, e.g. quercetin, juglone or curcumin. 
3) Type III consists of compounds that contain sufur, selenium or telluride, including 
1,2-[bis(1,2-benzisoselenazolone-3(2H)-ketone)]ethane (BBSKE); inhibition with the 
latter is reversible, which is unusual compared with the majority of TrxR inhibitors. 
4) Alkylating agents belong to type IV, such as carmustine or dinitrochlorobenzene. 
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2 AIMS OF THIS THESIS 
The following aims were addressed in this thesis: 
 Further validation of the cyclotherapy approach 
 Determination of new drug combinations to be used in cyclotherapy 
 Identification of structural analogs of former hit compounds and attribution of their 
mechanism of action 
 Investigation of the combination of HDACi TSA with p53-activator nutlin-3 
regarding the expression of p53 and its target genes as well as tumor cell survival 
 Discovery of p53-activating small molecules through a cell-based screen which exert 
a selective cytotoxic effect towards tumor cells, and determination of the mechanism 
of action thereof 
 Description of a study in which the use of tenovin-6 in zebrafish embryos led to an 
unexpected discovery 
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3 RESULTS AND DISCUSSION 
3.1 IDENTIFICATION OF NEW DRUG COMBINATIONS FOR CYCLOTHERAPY 
AND VALIDATION OF THE CYCLOTHERAPY CONCEPT (PAPER I) 
Cyclotherapy is an alternative approach to currently applied cancer therapies that was tested 
on cells for the first time almost 15 years ago (107). Even though studies testing nutlin-3 in 
this context showed very promising results (95, 139-143), this compound may not be the 
best-suited one for this approach. It has not been clinically approved yet, its in vivo efficacy is 
low  and very careful dosing would be required, since it has a very narrow working range, i.e. 
doses above 10 µM lead to DNA damage and doses below 2 µM have no detectable effects in 
cultured cells (43, 95, 144, 145). Therefore, we tested new drug combinations in comparison 
with nutlin-3 (paper I). To activate wt p53, we used tenovin-6, LMB, nutlin-3 and LDactD, 
which were shown to be non-genotoxic (102). The chemotherapeutics we subsequently 
applied were the M-phase (mitotic) poisons vinblastine (VNB) and vinorelbine (VRL), and 
the S-phase poisons cytosine arabinoside (Ara-C) and gemcitabine (GMTB), all of which are 
clinically approved.  
We first determined if tenovin-6, LMB, nutlin-3 and LDactD could induce cell cycle arrest in 
human normal dermal fibroblasts (HNDFs) without causing cell death, and if the effect on the 
cell cycle was reversible after removal of the compounds. Indeed, flow cytometric analyses 
indicated that each compound induced arrest in G1- and G2-phases of the cell cycle, an effect 
that was reversible after removal of the compounds. These data were confirmed by light 
microscopy (tenovin-6) and clonogenic assays (LMB).  
Next, we investigated whether the transient cell cycle arrest induced by p53 activators in 
normal cells could protect them from damage caused by the nucleoside analogs GMTB and 
Ara-C, which exert their toxic effects during S-phase of the cell cycle (146-148), or the vinca 
alkaloids VNB and VRL, which prevent microtubule formation and therefore inhibit mitosis 
(149). HNDFs were treated with p53-activating compounds for 24 hours prior to the addition 
of the chemotherapeutic drugs. Three days after treatment with the latter the cells were rinsed 
and given the chance to recover for several days. Following chemotherapy, i.e. treatment with 
S- or M-phase poisons alone, cells displayed nuclear aberrations, abnormal morphologies and 
impaired growth. In strong contrast, cells pre-incubated with p53 activators resembled 
untreated fibroblasts with normal nuclei, morphology, size and viability.  
The breast adenocarcinoma-derived cell lines MDA-MB-231 and MDA-MB-468 were used 
to investigate if the above-mentioned drug combinations have a cytotoxic effect in tumor 
cells expressing mutant p53 or if these would be protected from chemotherapeutic agents as 
well. Interestingly, the p53-activating compounds had varying effects on these cell lines, and 
can hence be classified into two groups, namely (1) tenovin-6 and LMB and (2) nutlin-3 and 
LDactD. As determined by flow cytometry and clonogenic assays, MDA-MB-231 cells 
neither induced cell cycle arrest nor became protected by nutlin-3 and LDactD. Interestingly, 
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LDactD made both p53-mutant cell lines more sensitive to the chemotherapeutic agents 
tested her. In contrast, tenovin-6 and LMB induced cell cycle arrest in G1-phase in MDA-
MB-231 cells and protected both p53-mutant cell lines from the cytotoxic effects of vinca 
alkaloids. In addition, tenovin-6 conferred protection from GMTB-induced damage in MDA-
MB-231 cells. This suggests that the combination of tenovin-6 with S-phase poisons might be 
safer than a combination with M-phase poisons. 
To further investigate the p53-dependence of tenovin-6, LMB, nutlin-3 and LDactD with 
regards to protection from chemotherapeutic agents, we performed experiments in HCT116 
cells following the same schedule as the one mentioned above, comparing p53-wt and p53-
deficient cells. Strikingly, only nutlin-3 specifically protected p53-wt expressing cells, 
whereas the other three compounds also protected p53-deficient cells. In some cases, the 
protective effect in p53-deficient cells was even stronger than in p53-wt cells. This may be 
due to the fact that nutlin-3 might be the most p53-specific compound used here, since it 
inhibits the direct interaction between p53 and its negative regulator MDM2 by binding to the 
p53 binding pocket in the latter (95). Targeting the deacetylases SirT and SirT2 (with 
tenovin-6 (98)), CRM1 (with LMB (104, 105)) and RNA polymerases (with LDactD (101, 
102)) might result in a number of additional effects besides p53 activation, which may 
explain the protection seen in p53-deficient cells.  
Furthermore, HCT116 p53-deficient cells might still able to express p53 isoforms which have 
N-terminal truncations (43, 44). Some of these isoforms may be tumor-promoting, but it 
should also be noted that they may in part be p53-wt dependent with regards to their 
expression or mode of action (40). Strikingly, nutlin-3 may not be able to affect these 
isoforms, since they may not be under control of MDM2 due to the lack of aa 18-23, i.e. the 
major binding site of MDM2 (79). Also LDactD eventually may exert its effects on p53 via 
inhibition of MDM2 (101, 102), but HCT116 p53-deficient cells were affected by LDactD. 
This discrepancy between nutlin-3 and LDactD may be explained by the notion that 
inhibition of RNA polymerases might have a much broader effect on cells than blockage of 
the p53 binding site in MDM2. 
Since the p53 activators used in this study caused polyploidy (8n DNA content) in HNDFs, 
we tested if this was due to de novo induction of endoreduplication or simply an 
accumulation in G2-phase of the cell cycle of those cells that had already been polyploid 
before treatment start. Therefore, we serum starved otherwise untreated HNDFs, which might 
be a quite mild technique to induce cell cycle arrest. Flow cytometric analyses indicated that 
also serum starvation led to polyploidy, suggesting that the four p53 activators tested here did 
not actively promote endoreduplication. 
In conclusion, LMB may be of use in cyclotherapy, but should not be combined with mitotic 
poisons, such as vinca alkaloids. Tenovin-6 only provided protection from treatment with one 
out of four chemotherapeutic agents, so its use in cyclotherapy would be restricted. Nutlin-3 
conferred protection of HNDFs, whereas p53-mutant cells were unaffected by this 
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compound. Therefore, it may be a better choice than tenovin-6 or LMB. However, all three 
compounds have not been clinically approved yet, so further alternatives are needed. LDactD 
may be a good candidate, since it is being used in the clinic and efficiently protected HNDFs 
but not p53-mutant cells against M- and S-phase poisons. Furthermore, it even had an 
additive effect together with the chemotherapeutics tested here in p53-mutant cells, which on 
one hand suggests that it does not act in a p53-dependent manner, which is supported by the 
data obtained using HCT116 p53-deficient cells, but also that LDactD may exert a double-
positive effect during cyclotherapy, i.e. protection of normal cells and active killing of tumor 
cells. Thus, LDactD might be the best choice of the compounds tested here. 
 
3.2 IDENTIFICATON OF A NOVEL TENOVIN WITH SIRT2-INHIBITORY 
FUNCTION (PAPER II) 
Paper II describes tenovin-D3, a structural analog of tenovin-1, which was a hit compound 
in one of the cell-based screens performed previously in our lab (98). Since tenovin-1 and its 
more water-soluble analog tenovin-6 display inhibitory activity towards the sirtuins SirT1 and 
SirT2, the inhibition of the latter two by tenovin-D3 was investigated. An in vitro assay using 
fluorescently labeled peptide substrates indicated that tenovin-D3 specifically inhibits SirT2, 
with an IC50 of 21.8 ± 2 µmol/L, but not SirT1 (IC50 of > 90 µmol/L). Inhibitory activity 
towards SirT2 was confirmed using α-tubulin derived from cell lysates as a substrate. In 
addition, deacetylation of α-tubulin derived from tenovin-D3-treated cells was detected by 
Western blotting (WB), an effect that was reversed upon overexpression of SirT2.  
In line with the model that simultaneous inhibition of SirT1 and SirT2 might be required for 
activation of p53, tenovin-D3 was neither able to induce p53 protein levels nor p53-
dependent transcription, as indicated by WB, CPRG assay and quantitative reverse 
transcription polymerase chain reaction (qRT-PCR). 
Interestingly, p21 levels were induced upon treatment with tenovin-D3, both at the mRNA 
and protein level. p21 was induced in cells expressing wt p53, mutant p53, no p53 or viral 
proteins promoting p53 degradation, but in general a stronger effect was seen in the absence 
of wt p53. There was a strong correlation between SirT2 inhibition and p21 induction, as 
suggested by the use of various structural analogs of tenovin-1 with SirT2-inhibitory or non-
inhibitory function, an increase in p21 levels upon transfection of cells with a dominant-
negative SirT2 mutant as well as the absence of cell cycle arrest in SirT2 knock-out cells 
upon treatment with tenovin-D3. However, the increase in p21 levels by tenovin-D3 was only 
partially reversed by SirT2 overexpression, whereas acetylation of α-tubulin upon tenovin-D3 
treatment was completely abolished in SirT2-overexpressing cells. This discrepancy may be 
due to off-target effects of tenovin-D3. It is unlikely that “classical” HDACs are affected by 
this compound, since they neither resemble sirtuins in their protein structure nor their cofactor 
dependence. Supporting this hypothesis, an in vitro assay suggested that HDAC8 was not 
inhibited by tenovin-D3. Also, co-treatment with tenovin-D3 and TSA, which is an inhibitor 
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of  most “classical” HDACs that was shown to induce p21 levels in a similar fashion to 
tenovin-D3 (papers II and III), had an additive effect on the increase in p21 levels. 
Furthermore, SirT3 was not inhibited by tenovin-D3. If other sirtuins were affected was 
difficult to investigate due to the lack of assays.  
Acetylation of α-tubulin has been suggested to play a role in cell migration, since 
deacetylation of α-tubulin upon inhibition of HDAC6 by tubacin can inhibit this cellular 
process (126). Acetylated α-tubulin is also a target of SirT2 and, indeed, short-term treatment 
with tenovin-D3 affected cell migration in a transwell assay. This reflected another parallel 
between tenovin-D3 and inhibitors of “classical” HDACs in addition to the above-mentioned 
effect of p21 expression (papers II and III).  
Two “classical” HDACi are in clinical use against cutaneous T-cell lymphoma (CTCL), i.e. 
vorinostat and romidepsin (150, 151). Since tenovin-D3 showed some similarities with the 
“classical” HDACi TSA, which in turn is structurally and functionally highly similar to 
SAHA (150), a potential future use of tenovin-D3 or other SirT2 inhibitors in CTCL or other 
malignancies could be an option for further investigation. Furthermore, SirT2 might play a 
role in neurodegenerative diseases (152), so tenovin-D3 or functionally similar compounds 
may be of potential use in this field as well.   
 
3.3 TSA INHIBITS P21 INDUCTION BY P53 AND VICE VERSA (PAPER III) 
The literature describing studies on the effects of TSA on p53 are partially contradictory. On 
one hand, TSA has been shown to stabilize the p53 protein, potentially by inhibition of 
HDAC1 and HDAC2, two deacetylases of p53 (62, 65, 128). On the other hand, the 
compound has also been shown to reduce p53 expression by decreasing p53 promoter activity 
or even destabilization of p53 mRNA (153, 154).  
Since nutlin-3 may exert a cytostatic effect in tumor cells, and induces and stabilizes HDM2, 
this compound may not lead to eradication of tumors (95, 155, 156). Here (paper III), we 
combined TSA and nutlin-3 to investigate if that combination could have a positive effect on 
p53 activation or if it even may lead to an enhanced cytostatic effect due to the ability of 
nutlin-3 and TSA to induce p21 in different ways.  
As shown by CPRG assay, WB and qRT-PCR, TSA was able to inhibit p53 transcriptional 
activity induced by nutlin-3 in tumor cells. This effect was specific for some p53 target genes, 
i.e. CDKN1A (p21), PIG3 and – to a weaker extent – HDM2, whereas NOXA was 
unaffected. This suggested that TSA, despite being a pan-HDACi, can have specific effects in 
cells. Strikingly, TSA treatment led to an induction of p21 and – again to a weaker extent – 
HDM2 mRNA and protein levels if used as a single agent, suggesting an incompatible effect 
with nutlin-3-induced p53. Similar results were obtained in HNDFs with the exception of 
HDM2, which was unaffected by TSA, both when used as single agent and in combination 
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with nutlin-3. The lack of effect on HDM2 mRNA levels in HNDFs may be related to the 
ability of TSA to induce the expression of p14ARF, which may lead to stabilization of HDM2 
(85, 157). Since de novo synthesized p53 levels might be reduced in TSA-treated HNDFs, as 
suggested by a decrease in p53 mRNA levels, there may be less transcriptionally active p53 
present in the cells, which eventually may result in decreased MDM2 transcription. Thus, a 
decrease in de novo synthesized MDM2 in combination with stabilized pre-existing MDM2 
protein may outbalance MDM2 protein levels and hence lead to a net equalization of MDM2 
protein levels in HNDFs. The gene encoding p14ARF (CDKN2A) is deleted in MCF7 cells, 
and one allele is deleted in HCT116 cells whereas the other allele is mutated and 
hypermethylated (158, 159); therefore, p14ARF is not expressed in these cell lines.  
In line with the literature, p53 mRNA levels were reduced upon TSA treatment, both in the 
presence and absence of nutlin-3 (153, 154). However, p53 protein levels were not affected 
and acetylation of Lys-382 was even enhanced. A change in the subcellular localization of 
p53 was not detected.   
We noticed that the induction of p21 protein by TSA in MCF7 cells and HNDFs, both of 
which express wt p53, was quite weak compared with the induction detected previously in 
MDA-MB-468 cells, which express mutant p53 (papers II and III). Indeed, by comparing 
HCT116 p53-wt and p53-deficient isogenic cell lines as well as in transfection experiments 
using the p53-null cell line H1299 we found that the presence of wt p53 interfered with the 
induction of p21 by TSA.  
Since the combination of TSA with nutlin-3 resulted in decreased p21 levels, the 
consequences thereof on the cell cycle were investigated. Nutlin-3 induced mainly an arrest 
in G1-phase of the cell cycle after 6 hours, whereas TSA led to an increase in cells entering 
S-phase and a slight increase in the percentage of cells in G2-phase after short-term treatment 
(i.e. 7 hours, since cells were always pre-treated with TSA for 1 hour prior to addition of 
nutlin-3). Co-treatment led to an intermediate result compared with single treatments. Also 
after long-term treatment this intermediate effect was detected, with the majority of cells 
undergoing G1- and G2-phase arrest. The high fraction of cells undergoing cell cycle arrest 
upon co-treatment suggested that the combination of HDACis and p53 activators may not be 
advantageous in a clinical setting. However, flow cytometric analyses after long-term 
treatment indicated that the combination of TSA and nutlin-3 led to an increase in the 
percentage of dead cells. In line with that, fewer colonies formed in a clonogenic assay upon 
co-treatment compared with single treatment of each compound, suggesting that the 
combination of such compounds may be safer than initially expected. It should be noted, 
however, that the drug combination tested here did not eradicate the cells, suggesting that it 
might be better to identify other combinations that are exclusively cytotoxic in cancer cells.  
Furthermore, our results may explain why HDACis such as TSA may improve the generation 
of iPSCs (132). One of the major problems with iPSC generation is the induction of 
activation of p53 and p21, resulting in senescence. Knockout of p53 has been shown to 
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improve iPSC generation, but also resulted in teratoma formation (160). Transient 
pharmacological inhibition of p53 may represent a safer method to obtain stem cells. 
However, also with this technique the risk of teratoma formation cannot be excluded and 
would require further investigation to proof its safety.  
 
3.4 IDENTIFICATION OF NOVEL P53 ACTIVATORS (PAPERS IV AND V) 
We performed a cell-based screen as described in subsection 1.2.5.6 in the human melanoma-
derived ARN8 cell line to test 20,000 small molecules derived from a chemical library 
provided by ChemBridge (San Diego, CA, USA) on their ability to activate p53. The two hit 
compounds MJ05 (paper IV) and MJ25 (paper V) were further studied due to different 
reasons: MJ05 appeared to be interesting due to its extremely high selectivity towards certain 
tumor cell lines with regards to the induction of cell death compared with other tumor cell 
lines as well as normal cells. MJ25 showed selectivity comparing melanoma cell lines and 
normal cells, and was furthermore selected due to its potential TrxR1-inhibitory capabilities. 
 
3.4.1 MJ05 (Paper IV) 
MJ05 was one of the top ranking compounds identified in this screen (paper IV). 
Pharmacokinetic studies suggested that this compound has a moderate to high plasma 
protein-binding capacity, which might be sufficient to fulfill the criteria of being a suitable 
drug candidate. Furthermore, MJ05 may not cause DSBs as suggested by the lack of 
induction of γ-H2AX and Ser-15 phosphorylated p53, suggesting that the compound may be 
safe with regards to genotoxicity. 
MJ05 induced p53 as well as its targets p21, MDM2 and PIG3, and this effect was stronger in 
ARN8 cells compared with HNDFs. These data confirmed the selectivity for tumor cells.  
Next, we tested if a combination of MJ05 with other p53-activating compounds would lead to 
an enhanced response in tumor cells. Indeed, MJ05 was highly cytotoxic in combination with 
nutlin-3 in ARN8 cells, even though nutlin-3 mainly induced cell cycle arrest as single agent. 
However, this effect was not seen when combined with tenovin-6 or LDactD. Importantly, 
nutlin-3 as well as the combination of nutlin-3 and MJ05 led to a cytostatic effect in HNDFs. 
MJ05 itself had no effect on HNDFs in that regard during the first two days of treatment, and 
a slight induction of cell cycle arrest could be detected after three days. These data confirmed 
tumor selectivity once again. 
The synergism between MJ05 and nutlin-3 suggested that these compounds may work 
through different mechanisms of action. Indeed, no binding of MJ05 to MDM2 (or MDMX) 
could be detected in vitro. Also, treatment of a number of tumor cells with differences in p53 
status indicated that a cytotoxic effect by MJ05 was not dependent on wt p53, but that there 
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was still selectivity within the cell lines tested, suggesting that the factor targeted by MJ05 
was not part of the p53 pathway. Further tests suggested that MJ05 neither inhibits 16 CDKs 
nor an additional ~150 kinases.  
Interestingly, MJ05 and nutlin-3 had a slightly more than additive effect on PIG3 induction in 
ARN8 cells at the mRNA and protein level, an effect also seen in HNDFs, but to a smaller 
extent and only at the mRNA level. In contrast, p21 levels were decreased upon co-treatment 
in ARN8 cells, an effect seen previously for tenovin-D3 (paper II) and TSA (papers II and 
III). However, this effect was not seen in HNDFs. These data suggest that the cytotoxic 
effect of MJ05 in tumor cells is the consequence of the strong induction of the pro-apoptotic 
protein PIG3 and a simultaneous reduction of p21. In HNDFs, the weak induction of PIG3 
combined with a strong induction of p21 might explain the observed cell cycle arrest.  
Since MJ05 treatment led to a slight reduction of -H2AX levels and failed to increase p53 
Ser-15 phosphorylation, we investigated if the compound could inhibit ataxia telangiectasia 
mutated (ATM) or ataxia telangiectasia and Rad3-related kinase (ATR) (161). However, this 
was not the case. 
We further discovered that MJ05 induced a delay in S-phase of the cell cycle, but not S-phase 
arrest. The absence of a change in phosphorylation of ATR / checkpoint kinase 1 (Chk1) 
suggested that this delay was not due to complete ribonucleotide depletion (162). We then 
tested whether MJ05 could delay S-phase progression by reducing replication fork assembly 
or firing. Cell division cycle 7 (Cdc7) kinase activity is required for the activation of 
replication origin helicases such as minichromosome maintenance complex component 2 
(MCM2) (163); however, MJ05 did not inhibit MCM2 phosphorylation. Next, we 
investigated if cell division cycle 6 (Cdc6) may be involved in S-phase delay upon MJ05 
treatment. The ATPase Cdc6 is a key factor in the licensing of replication origins prior to 
their activation (164). MJ05 reduced the levels of Cdc6 in a p53-independent manner in 
ARN8 cells and to a smaller extent in HNDFs. However, this did not happen in HCT116 p21-
/- cells, which also accumulated in S-phase upon MJ05 treatment. This finding combined with 
the fact that Cdc6 downregulation was quite a late event suggested that Cdc6 did not play a 
role in the S-phase delay seen here. Also, certain similarities between MJ05 and p14ARF, e.g. 
a p53-independent delay in S-phase progression (165, 166) or enhanced PIG3 expression in 
combination with nutlin-3, were detected. It may be quite unlikely that MJ05 acts like 
p14ARF, since p14ARF expression did not lead to a reduction in nutlin-3-induced p21 levels in 
tumor cells. However, it should be borne in mind that p14ARF was shown here to stabilize the 
p21 protein, which may prevent a reduction in its levels. 
MJ05 has a chiral center and hence exists as two enantiomers, (R)-MJ05 and (S)-MJ05. Our 
studies indicate that (R)-MJ05 is the only active enantiomer, suggesting that MJ05 may be 
specific regarding target inhibition.  
In vivo activity of (R)-MJ05 was tested in a xenograft study with ARN8 cells in SCID mice, 
both as a single agent and in combination with nutlin-3. MJ05 and nutlin-3 each affected 
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tumor growth and the combination resulted in an additive effect. In addition, MJ05 was tested 
alone and in combination with nilotinib, a drug that is clinically approved for the treatment of 
chronic myelogenous leukemia (CML) (167), on the ability to selectively kill leukemia stem 
cells (LSCs) derived from patients suffering from CML. Indeed, MJ05 efficiently induced 
apoptosis and inhibited growth of CML stem/progenitor cells ex vivo, alone and even stronger 
in the combination with nilotinib. 
The exact mechanism of action of MJ05 still needs to be elucidated. According to our data it 
is likely that MJ05 inhibits enzymes involved in the de novo synthesis of UMP and hence 
reduces pyrimidine ribonucleotide and pyrimidine deoxyribonucleotides levels, as uridine 
supplementation rescued ARN8 cells from the cytotoxic effects of this compound. Strikingly, 
MJ05’s cytotoxic effect occurred selectively in ARN8 cells but not in other tumor cell lines, 
not even those expressing wt p53. Instead, MJ05 induced cell cycle arrest or had a very mild 
effect in all other tumor cell lines as well as normal cells that express wt p53 and p21. This 
suggested that p53, which becomes activated upon MJ05 treatment, may detect the 
hypothesized reduction in (deoxy)ribonucleotide levels before all of them have vanished, 
upon which the compound halts the cell cycle until new (deoxy)ribonucleotides, in particular 
UMP and its derivatives UTP, CTP, dCTP and dTTP (figure 11, blue box), become available. 
In the less sensitive cell lines, activation of salvage pathways for pyrimidine nucleotide 
production may prevent MJ05’s effect. In addition, cytidine in combination with a UMP 
synthesis inhibitor (pyrazofurin) has been previously described to be cytotoxic due to a lack 
of expression of the salvage pathway enzyme cytidine deaminase (CDA) (168). Indeed, 
cytidine supplementation in combination with MJ05 killed more rapidly than MJ05 on its 
own. Confirming this hypothesis, A375 cells, which ARN8 cells are derived from (115), 
express low levels of CDA, suggesting that the salvage pathway rescuing cells from UMP 
depletion may not be fully functional in these cells. In line with that, other tumor cell lines 
tested in this study that did not die upon treatment with MJ05 – some of which even 
continued to proliferate – had been reported previously to express high levels of CDA. Thus, 
the salvage pathway might be functional in these cells, so that inhibition of de novo synthesis 
of UMP would not affect these cells tremendously.  
A question that remains is how p53 levels increase upon inhibition of an enzyme involved in 
UMP synthesis. Our data indicate that p53 mRNA levels did not change strongly upon MJ05 
treatment, although a slight increase was detectable in ARN8 cells. However, this increase 
may not be sufficient to explain the strong increase at the protein level. In addition, MJ05 did 
not increase p53 protein stability. Thus, another explanation would be an enhanced rate of 
translation. This seems illogical at first sight, since ribonucleotides are required for the 
synthesis of rRNA and tRNA, which in turn are needed for translation to take place, besides 
the mRNA serving as a template. However, based on the literature we propose the following 
model (figure 11, yellow box): MJ05 may reduce the levels of RNA-binding protein 38 
(RBM38) mRNA in ARN8 cells, since the 5’ end of the RBM38 mRNA is rich in cytidines. 
Because RBM38 binds to p53 mRNA and subsequently inhibits its translation, a reduction in 
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RBM38 levels may lead to an increase in p53 translation, at least in short-term when 
complete ribonucleotide depletion has not occurred yet. In addition, RBM38 has a stabilizing 
effect on p21 mRNA (169), which may explain why MJ05 reduces nutlin-3-induced p21 
protein levels. Furthermore, p53 induces RBM38. This would happen in case the salvage 
pathway is still functional, i.e. in those cells expressing high levels of CDA. Eventually, 
induction of RBM38 by MJ05 would reduce p53 levels after pyrimidine 
(deoxy)ribonucleotides levels are restored allowing cells to proliferate normally. 
  
Figure 11: de novo synthesis of UMP and its derivatives UTP, CTP, dCTP and dTTP (blue box) and a possible 
model on how p53 translation can take place in the absence thereof (yellow box). Abbreviations: CDA, cytidine 
deaminase; CTP, cytidine triphosphate; dCTP, deoxycytidine triphosphate; DHODH, dihydroorotate 
dehydrogenase; dTMP, deoxythymidine monophosphate; dTTP, deoxythymidine triphosphate; dUMP, 
deoxyuridine monophosphate; L-Gln, L-glutathione; RBM38, RNA-binding protein 38; UMP, uridine 
monophosphate; UMPS, uridine monophosphate synthetase. 
 
Altogether, MJ05 is a novel p53 activator that acts selectively in tumor cells. Furthermore, 
only those tumor cells may undergo cell death that have lost the salvage pathway for 
synthesis of pyrimidine (deoxy)ribonucleotides. The compound might have very few off-
target effects. In vivo and ex vivo data suggest that MJ05 may be a potential drug candidate 
worth studying further.  
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3.4.2 MJ25 and the identification of auranofin as a potential drug against 
melanoma (Paper V) 
The small molecule MJ25 is described in paper V. Even though it was a hit compound in our 
screen, it was not very potent at activating p53 as a single agent, albeit co-treatment with 
nutlin-3 enhanced p53 activation to some extent. Nevertheless, we considered this compound 
to be worth studying, since it had been found to be a potent inhibitor of the selenoenzyme 
TrxR1 in an in vitro screen (170). The combination of p53 activation and TrxR1 inhibition 
had previously been shown to be a successful strategy to kill tumor cells (171). Indeed, MJ25 
killed various melanoma cell lines after 72 hours of treatment, whilst being less toxic to 
HNDFs and human normal epithelial melanocytes (HNEMs).  
Importantly, the compound did not show signs of genotoxicity, as suggested by data on 
induction of γ-H2AX (representing DSBs) obtained by WB and an alkylation assay. 
A slight p53-dependence regarding execution of a cytotoxic effect and impairment of 
clonogenic potential was observed when comparing the wt-expressing tumor cell lines 
HCT116 and RKO with their p53-deficient counterparts. Interestingly, data obtained by WB 
suggested that MJ25 induced p21 in HNDFs and p53-mutant cell lines but not p53-wt 
expressing ARN8 cells. This further supported the data obtained by clonogenic assays and 
viability assays, suggesting that MJ25 may induce a cytostatic effect in cells that do not 
express wt p53, and therefore MJ25 would not be a suitable drug in the treatment of p53-
mutant cells. Furthermore, this finding combined with the fact that MJ25 is a weak p53 
activator suggests that this compound would not be a suitable candidate for cyclotherapy. 
All of the melanoma cell lines tested in this study harbor a mutation in the serine/threonine 
kinase BRAF (BRAFV600E) that leads to constitutive activation of the mitogen-activated 
protein kinase (MAPK) / extracellular signal-regulated kinase (ERK) signaling pathway 
(172). Since MJ25 was selective at killing cells expressing BRAFV600E, we investigated if the 
presence thereof played a role in this context. Indeed, MJ25 was slightly more potent at 
killing tumor cells expressing BRAFV600E than isogenic cells lacking this mutant protein. 
However, clonogenic assays, in which ARN8 cells were co-treated with the clinically 
approved BRAFV600E inhibitor vemurafenib (172, 173), as well as a WB analysis indicating 
upregulation of the downstream kinases  ERK1/2 upon treatment with MJ25 suggested that 
the compound might affect the BRAF pathway indirectly. 
Next, we studied the ability of MJ25 to inhibit the selenoenzyme TrxR1 in further detail. 
MJ25 could inhibit the enzyme obtained through protein synthesis from recombinant cDNA 
in vitro. Furthermore, it inhibited TrxR1 present in ARN8 cell lysates. However, MJ25 was 
less potent than auranofin (Ridaura), a TrxR1 inhibitor clinically approved for the treatment 
of rheumatoid arthritis (174-181). Both compounds were affected by supplementation of cells 
with sodium selenite prior and during treatment, which further suggested that these 
compounds act through TrxR1. Auranofin was more sensitive to this supplementation, 
suggesting once again that this drug might be more potent at inhibiting TrxR1 than MJ25. In 
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addition, both compounds induced increased levels of reactive oxygen species (ROS) and the 
expression of factors involved in the anti-oxidative response of the cell, further suggesting 
that TrxR1 was affected by MJ25. In line with the results mentioned above, auranofin was 
more potent at inducing some of these anti-oxidative factors and had more of a long-lasting 
effect than MJ25. Strikingly, when intracellular glutathione levels were nearly depleted, 
which leads to a stronger dependence of cells on the Trx system for an anti-oxidative 
response, only auranofin showed a marked increase in potency with regards to impaired cell 
viability. This suggested that MJ25 may have additional targets through which it exerts its 
cytotoxic effects towards melanoma cells. Further studies would be required in this respect.  
Interestingly, also auranofin showed some dependence on the MAPK/ERK signaling 
pathway with regards to impairment of melanoma cell clonogenic potential, and had, like 
MJ25, an additive effect when combined with vemurafenib. Similar to MJ25, auranofin 
induced phosphorylation (i.e. activation) of ERK1/2. This might be an indirect consequence 
of increased ROS levels upon treatment, as it has been reported previously that ROS can 
induce higher levels of phosphorylated ERK1/2 (182). Furthermore, a previous study showed 
that constitutively active BRAF activates the anti-oxidative protein Nrf2 (183), which in turn 
suggests that high ROS levels are present in cells expressing constitutively active BRAF. 
Thus, a further increase upon inhibition of TrxR1 might be lethal to cells expressing 
BRAFV600E. 
Strikingly, auranofin was able to eradicate whole melanoma cell populations at low 
micromolar concentrations. Vemurafenib, which is in clinical use, cannot achieve this. Also 
MJ25 was able to kill significantly more cells than vemurafenib, with almost no cells 
recovering from treatment. It should be noted, however, that MJ25 showed selectivity 
towards melanoma cells both in cell viability assays as well as clonogenic assays, whereas 
auranofin only did so in viability assays. 
The p53-dependence of auranofin was less clear than that of MJ25. First of all, even though 
auranofin induced p53 at the protein level, p53’s transactivational function was inhibited by 
auranofin, which became particularly clear when combined with nutlin-3. Furthermore, 
clonogenic potential of HCT116 cells was affected more strongly in the presence of full-
length p53, whereas RKO cells deficient in p53 were more sensitive to the drug than their 
p53-wt counterparts. These data suggest that auranofin may have off-target effects, and that 
these differ from the ones of MJ25.  
In contrast to MJ25, auranofin was not able to induce p21 protein levels in HNDFs. However, 
p21 was induced in p53-mutant cell lines, suggesting that this drug would not be suitable for 
the treatment of p53-mutant tumors. 
WB analyses of γ-H2AX suggested that auranofin may not be genotoxic. Furthermore, our 
data indicated that this drug was potent at killing melanoma cells. This was confirmed by a 
study in connection with the Developmental Therapeutics Program (DTP) by the National 
Cancer Institute (NCI) at the National Institutes of Health (NIH) 
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(http://dtp.nci.nih.gov/index.html) (184). Here, 60 tumor cell lines were tested on the ability 
of auranofin to affect cell viability. Nine melanoma cell lines were included, only one of 
which had been tested in our studies; hence the data from the DTP extended our data set. 
Importantly, all melanoma cell lines tested appeared to be highly sensitive to auranofin. Even 
though auranofin appeared to be cytotoxic towards HNDFs in clonogenic assays, this was not 
seen in another experimental setup, i.e. cell viability assays. Furthermore, auranofin is 
clinically approved for the treatment of rheumatoid arthritis and might therefore be tolerated 
by patients. If the doses required for cancer therapy would be in a similar range to those used 
against rheumatoid arthritis would, however, need to be investigated.  
Unfortunately, MJ25 is not very water-soluble at concentrations required for in vivo studies. 
Therefore, it could not be tested if this compound reduces the growth of xenografts. Chemical 
modification of the compound would be required to perform such studies. Simultaneously, 
one could perform structure-activity relationship (SAR) studies to identify structural analogs 
with enhanced potency.  
 
3.5 THE UNEXPECTED FINDING OF TENOVIN-6 CAUSING 
HYPOPIGMENTATION IN ZEBRAFISH EMBRYOS (PAPER VI) 
The study described in paper VI originally aimed at investigating if tenovin-6 was able to 
induce wt p53 in zebrafish (Danio rerio) embryos and what consequences that would have on 
metastasis formation. However, neither induction of p53 protein nor of mRNA of selected 
transcriptional targets could be detected in wt embryos after 10 hours of treatment, which was 
shown to be optimal for the CDK inhibitor roscovitine to induce p53 at the protein level (185, 
186). In contrast, an increase in the protein levels of mutant p53 (M214K) could be detected 
after 10 hours of treatment. Mutant p53 is more stable than wt p53 protein; hence this 
induction suggested that tenovin-6 essentially was able to induce p53. The lack of effect seen 
in wt embryos may be due to low stability of the tenovin-6 compound, so it may be possible 
that wt p53 only became induced for a very short time in zebrafish embryos upon treatment, 
and this time may not have been long enough for target gene transcription to occur.  
Next to the induction of mutant p53, there were further indications that tenovin-6 was 
bioactive in the embryos: First, treatment was lethal, and this effect was dose- and time-
dependent; in line with the lack of wt p53 induction, no strong correlation between p53 status 
and lethality was detected. Second, the p53 target gene PUMA was induced by tenovin-6, 
both in wt and p53-mutant embryos. This suggested that proteins other than p53 were 
responsible for this effect. The p53 paralog p73 may be a candidate, since it transactivates 
PUMA and was shown to be regulated by SirT1, i.e. a target of tenovin-6 (187-189). Third, 
tenovin-6 caused long-lasting hypopigmentation in zebrafish embryos. 
The exact mechanism behind the observed hypopigmentation after tenovin-6 treatment has 
not been elucidated yet. The compound might inhibit a factor / factors directly or indirectly 
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involved in pigmentation. Tenovin-6 did not inhibit tyrosinase, a key enzyme in 
melanogenesis, in an assay using cell lysate derived from murine pigmented melanoma cells 
and human melanocytes. This was unexpected, since tenovin-6 is structurally related to N-
phenylthiourea (PTU), which inhibits tyrosinase through copper chelation and is widely used 
to prevent pigmentation in zebrafish embryos (190). PTU did not activate p53 in a CPRG 
assay, which again was different from the action of tenovin-6. This might be a very positive 
finding, though, since PTU is commonly used in zebrafish experiments, and constitutive 
activation of p53 otherwise could have affected the outcome of a large number of them. 
A potential tenovin-6 target candidate could be vacuolar H+-ATPase (V-ATPase), a proton 
pump required for the establishment of the acidic environment present in lysosomes and 
lysosome-like organelles such as melanosomes. Zebrafish embryos in which V-ATPase is 
mutated (called Mustard) show a phenotype resembling that of tenovin-6, and so does the 
phenotype of embryos treated with the V-ATPase inhibitor bafilomycin A1 (bafA1) (191, 
192). The latter compound has been shown to inhibit autophagy, a cellular process in which 
unnecessary and dysfunctional cellular components (e.g. damaged organelles) are degraded 
(193). Lysosomal enzymes are needed for this process and hence requires the fusion of 
autophagosomes with lysosomes (194). Tenovin-6 is thought to block autophagy after fusion 
of autophagosomes and lysosomes has occurred, as suggested by accumulation of early (non-
acidic) and late (acidic) autophagosomes as well as accumulation of the autophagy-marker 
LC3B-II (192, 195) (Ladds et al., unpublished data). Tenovin-6 is thought to accumulate in 
the acidic environment of late autophagosomes and lysosomes due to the presence of a 
tertiary amine in its chemical structure; in addition, co-treatment with bafA1 did not lead to 
an enhanced level of LC3B-II, and this has been suggested to be due to different functions of 
bafA1 and tenovin-6 with regards to autophagy (192, 195). However, it cannot be excluded 
that tenovin-6 and bafA1 fulfill exactly the same function. The presence of tenovin-6 in late 
autophagosomes / lysosomes has not been shown yet, but would answer the question which 
step of autophagy is affected by this compound. An additional argument for the potential 
inhibition of V-ATPase by tenovin-6 is that a yeast strain hemizygous for vacuolar H+/Ca2+ 
exchanger 1 (VCX1) was hypersensitive to tenovin-6 (98). Vcx1p is a vacuolar H+/Ca2+ 
antiporter that transports Ca2+ into vacuoles to maintain the cytoplasmic Ca2+ homeostasis 
and is dependent on the proton gradient established by V-ATPase (196-198). Thus, 
hemizygosity for VCX1 might lead to hypersensitivity of the yeast strain to further 
interference with the machinery that regulates proton levels inside vacuoles, eventually 
leading to constitutively elevated Ca2+ levels in the cytoplasm, which might be a toxic 
condition.  
In conclusion, our studies in zebrafish embryos led to the unexpected discovery that tenovin-
6 causes hypopigmentation. Furthermore, a new target of the compound may have been 
identified.  
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